$Amazing $Biotech & $olid $Microcap $tocks

[kei]

PLX - Protalix BioTherapeutics Announces Presentation of Phase II Clinical Trial Results for alidornase alfa in Cystic Fibrosis at the 40th European Cystic Fibrosis Society Conference

https://finance.yahoo.com/news/protalix-biotherapeutics-announces-presentation-phase-113000139.html

GlobeNewswire•May 23, 2017Comment
CARMIEL, Israel, May 23, 2017 (GLOBE NEWSWIRE) -- Protalix BioTherapeutics, Inc. (PLX) (PLX), announced today that an oral presentation highlighting the results from the Company’s phase II clinical trial of alidornase alfa (PRX-110) for the treatment of Cystic Fibrosis (CF) and including new clinical data will be given at the 40th European Cystic Fibrosis Society Conference which is being held June 7-10, 2017 in Seville, Spain.

The oral presentation, titled “Phase II clinical trial results of alidornase alfa for the treatment of cystic fibrosis,” will be given by Professor Eitan Kerem, Head of the Division of Pediatrics, Children’s Hospital, Hadassah Medical Center, and principal investigator of the clinical trial on Wednesday, June 7 from 3:00pm to 4:30pm CET as a part of a workshop titled, “The airway surface, mucus and inflammation – new treatments.” An archived copy of the presentation will be available following the conference at www.protalix.com on the presentations tab of the investor page.

Alidornase alfa is a plant cell-expressed, chemically-modified recombinant DNase enzyme resistant to inhibition by actin, which the Company has specifically designed to enhance the enzyme’s efficacy in CF patients. Sixteen patients enrolled and completed the phase II clinical trial.